Marqibo is a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse …

May 2, 2022 · The U.S. Food and Drug Administration (FDA) has withdrawn approval of MARQIBO (vincristine sulfate liposome injection) after a postmarking clinical trial failed to …

Nov 21, 2023 · Marqibo is a cancer medication that interferes with the growth of cancer cells and slows their spread in the body. Marqibo is used to treat a type of blood cancer called …

Marqibo® is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has...

Dec 3, 2015 · Marqibo®, vincristine sulfate liposome injection, uses a novel sphingomyelin and cholesterol nanoparticle that facilitates vincristine dose intensification without exacerbation of …

Aug 10, 2012 · The FDA has approved vincristine sulfate liposome injection (Marqibo) to treat adults with Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL).

Nov 3, 2022 · Marqibo (vinCRIStine sulfate liposome injection) is a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic …

Marqibo is a liposomal formulation of vincristine, which has been developed with the intention to increase the tolerable dose of the active moiety, vincristine, while reducing its dose...

Vincristine sulfate liposome injection (VSLI), Marqibo ®, is a sphingomyelin and cholesterol-based nanoparticle formulation of VCR that was designed to overcome the dosing and …

Medscape - Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) dosing for Marqibo (vincristine liposomal), frequency-based adverse effects, comprehensive interactions,...